Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 1;33(6):433-439.
doi: 10.1097/GCO.0000000000000751.

Oestrogen component of COCs: have we finally found a replacement for ethinyl estradiol?

Amy J Voedisch  1 , Wing Kay Fok  2
Affiliations
Review

Oestrogen component of COCs: have we finally found a replacement for ethinyl estradiol?

Amy J Voedisch et al. Curr Opin Obstet Gynecol. .

Abstract

Purpose of review: Combined oral contraceptive pills are among the most widely used contraceptive methods globally. Despite their popularity, the potential risks and side effects can lead to both high discontinuation rates and adverse outcomes including thromboembolic events. The quest for a safer alternative to the traditional ethinyl estradiol/progestin combination has led to the use of newer oestrogens. Ethinyl oestradiol alternatives will be reviewed including the newest option, estetrol, as it enters clinical use.

Recent findings: Oestradiol, when combined with a progestin with strong endometrial activity, is a viable alternative to ethinyl estradiol in the form of oestradiol valerate and estradiol, which have been available since 2008 and 2011, respectively. Estetrol is the newest oestrogen available and is found naturally in the foetal liver. Estetrol was approved for use in 2021. All three of these alternatives have high contraceptive efficacy, similar if not improved cycle control and decreased impact on haemostatic factors as compared to ethinyl estradiol.

Summary: Alternatives to ethinyl oestradiol, including the newest option of estetrol, show promise in providing comparable contraceptive efficacy with potentially lower risk of side effects and thromboembolic events.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Kavanaugh ML, Pliskin E. Use of contraception among reproductive-aged women in the United States, 2014 and 2016. F S Rep 2020; 1:83–93.
    1. Bearak JM, Jones RK. Did contraceptive use patterns change after the Affordable Care Act? A descriptive analysis. Womens Health Issues 2017; 27:316–321.
    1. Jeffrey JT, Creinin M. Speroff & Darney's clinical guide to contraception. 6th ed. 2020; Philadelphia: Wolters Kluwer, 2020.
    1. Grandi G, Chiara Del Savio M, Lopes da Silva-Filho A, et al. Estetrol (E4): the new estrogenic component of combined oral contraceptives. Expert Rev Clin Pharmacol 2020; 13:327–330.
    1. Borgelt L, Martell C. Estradiol valerate/dienogest: a novel combined oral contraceptive. Clin Therap 2012; 34:37–55.